IKT-701

N/A

Report date: 2026/03/19 16:58:13

Base Information

Drug NameIKT-701

Drug Alias Nameanti-CD3/anti-EpCAM bispecific T-cell engager-expressing CAR T-cell therapy (Icell Kealex)EpCAM-TEA-VV-loaded CAR T-cell therapy (Icell Kealex Therapeutics)IKT-701

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein +[4]

Mechanisms of ActionEpithelial cell adhesion molecule modulatorsT cell surface glycoprotein CD3 modulators

TargetsT cell surface glycoprotein CD3Epithelial cell adhesion molecule

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesIcell Kealex Therapeutics

China Registration ClassN/A

Develop Information

Active CompaniesIcell Kealex Therapeutics

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A